软组织生物製品管道 - 发展阶段、细分市场、地区和国家、监管途径、主要参与者（2024 年版）

该报告检查和分析了软组织生物製品管道产品，并提供了全面的信息，包括不同开发阶段的产品的比较分析和正在进行的临床试验的数据。

目录

第1章 目录

第2章简介

第3章 开发中产品

• 软组织生物製品 - 管道产品：依开发阶段划分
• 软组织生物製剂 - 管道产品：按细分市场
• 软组织生物製品 - 管道产品：按地区
• 软组织生物製品 - 管道产品：依监管途径
• 软组织生物製品 - 管道产品：按预计批准日期
• 软组织生物製剂 - 正在进行的临床试验

第4章 软组织生物製剂－各公司在研产品

• 软组织生物製品公司 - 管道产品：依开发阶段
• 软组织生物製品 - 管道产品：依开发阶段划分

第5章 软组织生物製品公司及产品概述

• Acuitive Technologies Inc：公司概况
  • Acuitive Technologies Inc：管道产品和正在进行的临床试验概述
• Anika Therapeutics Inc：公司概况
  • Anika Therapeutics Inc：管道产品和正在进行的临床试验概述
• BioGend Therapeutics 有限公司：公司概况
  • BioGend Therapeutics Co Ltd：管道产品和正在进行的临床试验概述
• Colorado Therapeutics, LLC：公司概况
  • Colorado Therapeutics, LLC：管道产品和正在进行的临床试验概述
• Columbia University：公司概况
  • Columbia University：管道产品和正在进行的临床试验概述
• Core Essence Orthopedics, LLC：公司概况
  • Core Essence Orthopedics, LLC：管道产品和正在进行的临床试验概述
• Georgia Institute of Technology：公司概况
  • Georgia Institute of Technology：管道产品和正在进行的临床试验概述
• New York R&D Center for Translational Medicine and Therapeutics Inc：公司概况
  • New York R&D Center for Translational Medicine and Therapeutics Inc：管道产品和正在进行的临床试验概述
• Nutech Medical Inc：公司概况
  • Nutech Medical Inc：管道产品和正在进行的临床试验概述
• OHSU Knight Cancer Institute：公司简介
  • OHSU Knight Cancer Institute：管道产品和正在进行的临床试验概述
• Osteopore International Pte Ltd：公司概况
  • Osteopore International Pte Ltd：管道产品和正在进行的临床试验概述
• Shandong Junxiu Biotechnology Co Ltd：公司概况
  • Shandong Junxiu Biotechnology Co Ltd：在研产品概况及正在进行的临床试验
• STEL Technologies LLC：公司概况
  • STEL Technologies LLC：管道产品和正在进行的临床试验概述
• Tissue Regenix Group PLC：公司概况
  • Tissue Regenix Group PLC：管道产品和正在进行的临床试验概述
• University of Arizona：公司概况
  • University of Arizona：管道产品和正在进行的临床试验概述
• University of Bielefeld：公司概况
  • University of Bielefeld：管道产品和正在进行的临床试验概述
• University of Minnesota：公司概况
  • University of Minnesota：管道产品和正在进行的临床试验概述
• University of Missouri：公司概况
  • University of Missouri：管道产品和正在进行的临床试验概述
• University of Zurich：公司概况
  • University of Zurich：管道产品和正在进行的临床试验概述

第6章 软组织生物製品 - 最新进展

• 2024 年 8 月 27 日：Chinese Academy of Sciences，3D 生物列印材料具有改善骨骼和软组织修復的潜力
• 2024 年 8 月 12 日：Biorez、BioBrace Reinforced Implant获得 510(K) 批准
• 2024 年 6 月 11 日：Allosource 推出 Aceconnex，这是首款用于髋关节盂唇重建和加强的缝合筋膜装置
• 2024 年 5 月 2 日：Organogenesis，膝关节炎治疗 ReNu 3 期临床试验达成主要评价项目
• 2023 年 11 月 2 日：Humacyte 于 2023 年 11 月 9 日公布第三季财务业绩，并提供公司最新动态
• 2023 年 10 月 31 日：案例研究显示 BioTissue 的创新人类羊膜同种异体移植物可有效治疗复杂的足部溃疡和创伤

第7章附录

GlobalData's Medical Devices sector report, "Soft Tissue Biologics Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Soft Tissue Biologics pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. Soft Tissue Biologics market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles's tendon.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the Soft Tissue Biologics under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Soft Tissue Biologics and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Soft Tissue Biologics under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Soft Tissue Biologics Overview

3 Products under Development

• 3.1 Soft Tissue Biologics - Pipeline Products by Stage of Development
• 3.2 Soft Tissue Biologics - Pipeline Products by Segment
• 3.3 Soft Tissue Biologics - Pipeline Products by Territory
• 3.4 Soft Tissue Biologics - Pipeline Products by Regulatory Path
• 3.5 Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
• 3.6 Soft Tissue Biologics - Ongoing Clinical Trials

4 Soft Tissue Biologics - Pipeline Products under Development by Companies

• 4.1 Soft Tissue Biologics Companies - Pipeline Products by Stage of Development
• 4.2 Soft Tissue Biologics - Pipeline Products by Stage of Development

5 Soft Tissue Biologics Companies and Product Overview

• 5.1 Acuitive Technologies Inc Company Overview
  • 5.1.1 Acuitive Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 Anika Therapeutics Inc Company Overview
  • 5.2.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.3 BioGend Therapeutics Co Ltd Company Overview
  • 5.3.1 BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.4 Colorado Therapeutics, LLC Company Overview
  • 5.4.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.5 Columbia University Company Overview
  • 5.5.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
• 5.6 Core Essence Orthopaedics, LLC Company Overview
  • 5.6.1 Core Essence Orthopaedics, LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.7 Georgia Institute of Technology Company Overview
  • 5.7.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
• 5.8 New York R&D Center for Translational Medicine and Therapeutics Inc Company Overview
  • 5.8.1 New York R&D Center for Translational Medicine and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.9 Nutech Medical Inc Company Overview
  • 5.9.1 Nutech Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.10 OHSU Knight Cancer Institute Company Overview
  • 5.10.1 OHSU Knight Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview
• 5.11 Osteopore International Pte Ltd Company Overview
  • 5.11.1 Osteopore International Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.12 Shandong Junxiu Biotechnology Co Ltd Company Overview
  • 5.12.1 Shandong Junxiu Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.13 STEL Technologies LLC Company Overview
  • 5.13.1 STEL Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.14 Tissue Regenix Group PLC Company Overview
  • 5.14.1 Tissue Regenix Group PLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.15 University of Arizona Company Overview
  • 5.15.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview
• 5.16 University of Bielefeld Company Overview
  • 5.16.1 University of Bielefeld Pipeline Products & Ongoing Clinical Trials Overview
• 5.17 University of Minnesota Company Overview
  • 5.17.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
• 5.18 University of Missouri Company Overview
  • 5.18.1 University of Missouri Pipeline Products & Ongoing Clinical Trials Overview
• 5.19 University of Zurich Company Overview
  • 5.19.1 University of Zurich Pipeline Products & Ongoing Clinical Trials Overview

6 Soft Tissue Biologics- Recent Developments

• 6.1 Aug 27, 2024: Chinese Academy of Sciences : 3D Bioprinting Materials Offer Possibility for Better Bone and Soft Tissue Repair
• 6.2 Aug 12, 2024: Biorez Receives 510(K) Clearance for BioBrace Reinforced Implant
• 6.3 Jun 11, 2024: Allosource Launches Aceconnex, First Pre-sutured Fascia Device for Hip Labral Reconstruction and Augmentation
• 6.4 May 02, 2024: Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
• 6.5 Nov 02, 2023: Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
• 6.6 Oct 31, 2023: BioTissue's Innovative Human Amniotic Allografts Show Efficacy in Treating Complex Foot Ulcers and Traumatic Wounds in Case Studies

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer

List of Tables

• Soft Tissue Biologics - Pipeline Products by Stage of Development
• Soft Tissue Biologics - Pipeline Products by Segment
• Soft Tissue Biologics - Pipeline Products by Territory
• Soft Tissue Biologics - Pipeline Products by Regulatory Path
• Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
• Soft Tissue Biologics - Ongoing Clinical Trials
• Soft Tissue Biologics Companies - Pipeline Products by Stage of Development
• Soft Tissue Biologics - Pipeline Products by Stage of Development
• Glossary

List of Figures

• Soft Tissue Biologics - Pipeline Products by Stage of Development
• Soft Tissue Biologics - Pipeline Products by Segment
• Soft Tissue Biologics - Pipeline Products by Territory
• Soft Tissue Biologics - Pipeline Products by Regulatory Path
• Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
• Soft Tissue Biologics - Ongoing Clinical Trials